VMAT2-IN-I HCl

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562539

CAS#: 1436695-49-6

Description: VMAT2-IN-I HCl is a vesicular monoamine transporter-2 (VMAT2) inhibitor, with 15-​fold greater affinity than GZ-​793A.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-11. Prices are subject to change without notice.

VMAT2-IN-I HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562539
Name: VMAT2-IN-I HCl
CAS#: 1436695-49-6
Chemical Formula: C25H32ClF4NO4
Exact Mass:
Molecular Weight: 521.97
Elemental Analysis: C, 57.53; H, 6.18; Cl, 6.79; F, 14.56; N, 2.68; O, 12.26


Synonym: VMAT2-IN-I HCl; VMAT2 IN I HCl; VMAT2INI HCl; VMAT2 IN I Hydrochloride; VMAT2INI Hydrochloride; VMAT2-IN-I Hydrochloride;

IUPAC/Chemical Name: 3-{2(S),5(R)-Bis-[2-(4-difluoromethoxy-phenyl)-ethyl]-pyrrolidin-1-yl}-propane-1,2(R)-diol Hydrochloride

InChi Key: IUOHFZVLXJSQCL-SXWPHCFWSA-N

InChi Code: InChI=1S/C25H31F4NO4.ClH/c26-24(27)33-22-11-3-17(4-12-22)1-7-19-9-10-20(30(19)15-21(32)16-31)8-2-18-5-13-23(14-6-18)34-25(28)29;/h3-6,11-14,19-21,24-25,31-32H,1-2,7-10,15-16H2;1H/t19-,20+,21-;/m1./s1

SMILES Code: OC[C@H](O)CN1[C@@H](CCC2=CC=C(OC(F)F)C=C2)CC[C@H]1CCC3=CC=C(OC(F)F)C=C3.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Citrome L. Reprint of: Clinical management of tardive dyskinesia: Five steps to success. J Neurol Sci. 2018 Jun 15;389:61-66. doi: 10.1016/j.jns.2018.02.037. Epub 2018 Feb 28. Review. PubMed PMID: 29519687.

2: Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018. Review. PubMed PMID: 29497277; PubMed Central PMCID: PMC5818866.

3: Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci. 2018 Jun 15;389:1-3. doi: 10.1016/j.jns.2018.02.009. Epub 2018 Feb 5. Review. PubMed PMID: 29449008.

4: Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci. 2018 Jun 15;389:43-47. doi: 10.1016/j.jns.2018.02.006. Epub 2018 Feb 5. Review. PubMed PMID: 29433808.

5: Lin CC, Ondo WG. Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J Neurol Sci. 2018 Jun 15;389:48-54. doi: 10.1016/j.jns.2018.02.014. Epub 2018 Feb 5. Review. PubMed PMID: 29433806.

6: Sarva H, Henchcliffe C. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23. Review. PubMed PMID: 29338466.

7: Citrome L. Clinical management of tardive dyskinesia: Five steps to success. J Neurol Sci. 2017 Dec 15;383:199-204. doi: 10.1016/j.jns.2017.11.019. Epub 2017 Nov 16. Review. PubMed PMID: 29246613.

8: Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13030. Epub 2017 Oct 12. Review. PubMed PMID: 29024264.

9: Kim ES. Valbenazine: First Global Approval. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review. PubMed PMID: 28578484.

10: Citrome L. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12. Review. PubMed PMID: 28497864.

11: Barquero N. Valbenazine for the treatment of tardive dyskinesia. Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review. PubMed PMID: 28276538.

12: Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review. PubMed PMID: 28044943.

13: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review. PubMed PMID: 27819145.

14: Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011 Jul;31(4):483-519. doi: 10.1002/med.20187. Epub 2010 Feb 4. Review. PubMed PMID: 20135628; PubMed Central PMCID: PMC3019297.